What is VRTX stock price today?

VRTX (Vertex Pharmaceuticals Inc) stock is trading at $496.83 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is VRTX stock going up or down today?

VRTX stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy VRTX stock now?

The decision to buy VRTX depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is VRTX a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for VRTX based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is VRTX stock overvalued or undervalued?

VRTX currently trades at a P/E ratio of 31.34, which may indicate premium valuation. Our DCF calculator provides intrinsic value estimates to help determine if VRTX is fairly priced.

What is VRTX's P/E ratio?

VRTX has a price-to-earnings (P/E) ratio of 31.34, which measures how much investors are willing to pay per dollar of earnings. Compare this to industry peers and historical averages for context.

What is VRTX's market cap?

VRTX (Vertex Pharmaceuticals Inc) has a market capitalization of $121.95 billion, making it a mid-cap stock.

What is VRTX's price to book ratio?

VRTX trades at a price-to-book (P/B) ratio of 6.10, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does VRTX pay dividends?

VRTX does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is VRTX's dividend yield?

VRTX does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is VRTX stock a good long-term investment?

VRTX's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is VRTX's revenue growth rate?

VRTX has shown revenue growth of 0.1% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

Yes, VRTX is profitable with a profit margin of 0.3%. This indicates the company generates 0.3 cents of profit for every dollar of revenue.

What are the risks of investing in VRTX?

Key risks for VRTX include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does VRTX compare to its competitors?

Compare VRTX to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize VRTX's performance and positioning.

What is VRTX's stock price target for 2026?

Our AI model provides price targets for VRTX based on fundamental analysis: Bull case $645.88 (+30%), Base case $571.35 (+15%), Bear case $447.15 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about VRTX?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for VRTX. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is VRTX's next earnings report?

VRTX reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

VRTX - Vertex Pharmaceuticals Inc

NYSE * Health Care * Biotechnology

$496.83

+$16.70 (+3.48%)

About Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

VRTX Key Statistics

Market Cap

$121.95B

P/E Ratio

31.34

P/B Ratio

6.10

EPS

$15.32

Revenue Growth

+0.1%

Profit Margin

0.3%

Employees

6,400

How VRTX Compares to Peers

VRTX trades at a premium valuation vs peers (highest P/E)

VRTX has the highest profit margins in Biotechnology

VRTX has the fastest revenue growth among competitors

P/E Rank

of 5

Margin Rank

of 6

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
VRTX(This stock)	$121.95B	31.3	0%	0.3%	-
AMGNAmgen Inc	$204.48B	26.7	0%	0.2%	vs AMGN
GILDGilead Sciences	$178.37B	21.2	0%	0.3%	vs GILD
REGNRegeneron Pharmaceuticals	$81.49B	18.6	0%	0.3%	vs REGN
BIIBBiogen Inc	$28.15B	21.8	-0%	0.1%	vs BIIB
MRNAModerna Inc	$20.93B	N/A	-0%	-1.5%	vs MRNA

Vertex Pharmaceuticals Inc Company Information

Headquarters: Massachusetts; U.S.A
Website: www.vrtx.com
Sector: Health Care
Industry: Biotechnology

VRTX - Vertex Pharmaceuticals Inc

About Vertex Pharmaceuticals Inc

VRTX Key Statistics

How VRTX Compares to Peers

Vertex Pharmaceuticals Inc Company Information

VRTX Lician Score

VRTX Financial Snowflake

Upcoming Events for VRTX